Carrying therapeutic cargoes across the blood-brain barrier to fight DIPG
IRB, Instutut de recerca Biomèdica, Spain
The Blood-Brain Barrier (BBB) is a natural and protective barrier that separates the brain from the circulatory system. This barrier is the bottleneck for the more than 98% of CNS (Central Nervous System) drug candidates that fail to cross it.
The G2B shuttles could save the preclinical development of several existing drug candidates for CNS diseases that are rejected because of their inability to cross the BBB.
The project aims to address two main goals: first, to advance the preclinical development of the flagship product, G2B-4-DIPG. This product is a new therapeutic approach for Diffuse Intrinsic Pontine Glioma using the team’s peptide-shuttles to carry the effective chemotherapeutic drug to the brain to fight against this devastating paediatric brain tumor. With G2B-4-DIPG, the second goal will be achieved: the validation of the use of the Gate2Brain platform in a therapeutic context.